Alport Syndrome

1. Disease Information

1.1 Overview / definition

Alport syndrome is a hereditary glomerular nephropathy due to defects in the α3–α4–α5 type IV collagen network of basement membranes, especially the glomerular basement membrane (GBM), driven by pathogenic variants in COL4A3, COL4A4, and COL4A5. (kang2024acomprehensivereview pages 1-3, torra2025diagnosismanagementand pages 1-2)

A widely used clinical framing is the kidney–ear–eye triad: kidney disease with persistent haematuria progressing to CKD/kidney failure, plus hearing loss and ocular abnormalities. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 3-5)

1.2 Key identifiers (available from tool-accessible sources)

• MONDO: MONDO_0018965 (Alport syndrome) (torra2025diagnosismanagementand pages 1-2)
• OMIM disease IDs (from primary abstract text): Alport syndrome OMIM#308940; X-linked OMIM#301050; autosomal recessive OMIM#203780; autosomal dominant OMIM#104200 (liang2023moleculardynamicsand pages 1-2)
• Causal genes (OMIM gene entries cited in abstract): COL4A5 (OMIM*303630), COL4A3 (OMIM*120070), COL4A4 (OMIM*120131) (liang2023moleculardynamicsand pages 1-2)

Not retrievable with current tool evidence: Orphanet ORPHA ID, ICD-10/ICD-11 codes, and MeSH ID were not present in the retrieved documents/records and therefore cannot be asserted here without external database access.

1.3 Synonyms / alternative names

• “X-linked Alport syndrome (XLAS)”, “autosomal recessive Alport syndrome (ARAS)”, “autosomal dominant Alport syndrome (ADAS)” (liang2023moleculardynamicsand pages 1-2)
• “COL4A3/4/5 glomerulopathy” is used in guideline framing for the broader genotypic spectrum (torra2025diagnosismanagementand pages 1-2)
• “Alport spectrum” has been discussed as an umbrella term in genomics-era nomenclature discussions. (daga2022the2019and pages 3-4)

1.4 Evidence provenance: patient-level vs aggregated resources

Evidence summarized below is derived from (i) expert guideline consensus (systematic review + graded recommendations), (ii) peer-reviewed reviews, (iii) observational cohorts/case series, and (iv) ClinicalTrials.gov trial registry records. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 5-6, NCT02855268 chunk 1)

2. Etiology

2.1 Disease causal factors

Primary causal factor: germline pathogenic variants affecting type IV collagen α3/α4/α5 chain formation, encoded by COL4A3, COL4A4, COL4A5. (kang2024acomprehensivereview pages 1-3, torra2025diagnosismanagementand pages 1-2)

Mechanistic framing: mutations disrupt α3α4α5(IV) heterotrimer formation and basement membrane integrity, rendering the GBM vulnerable under filtration pressure, leading to haematuria and progressive injury. (kang2024acomprehensivereview pages 1-3)

2.2 Risk factors

• Genetic risk: inheritance mode and variant type strongly influence risk of early kidney failure (e.g., severe disease in males with XLAS; earlier and more severe course in ARAS than ADAS). (kang2024acomprehensivereview pages 5-6, kang2024acomprehensivereview pages 3-5)
• Proteinuria is emphasized as a major risk factor for progression to CKD/ESKD in Alport syndrome. (kang2024acomprehensivereview pages 3-5)

Candidate genetic modifiers: co-occurring variants in podocyte or non-collagenous ECM genes (e.g., CRB2, LAMA5, LAMB2, NUP107, MYO1E, PLCE1) may contribute to phenotypic variability (nephrotic-range proteinuria, FSGS, ESKD) in some patients, based on a small case series. (lujinschi2025candidategeneticmodifiers pages 1-2)

2.3 Protective factors

Direct genetic or environmental protective factors were not identified in the retrieved evidence set.

2.4 Gene–environment interactions

Direct gene–environment interaction evidence for Alport syndrome was not identified in the retrieved evidence set.

3. Phenotypes

3.1 Core renal phenotypes

• Persistent microscopic haematuria (hallmark feature) with subsequent proteinuria and progressive decline in kidney function. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 3-5)
• Pediatric cohort example (Southwestern China): hematuria + proteinuria in 85% (34/40); pure hematuria 15% (6/40); nephrotic-range proteinuria in 10/40. (chen2025novelcol4a3–col4a5variants pages 3-4)

Suggested HPO terms (examples): - Hematuria HP:0000790 - Proteinuria HP:0000093 - Chronic kidney disease HP:0012622 - End-stage renal disease HP:0003774

3.2 Auditory phenotypes

• Sensorineural hearing loss is common and progressive; one review reports (XLAS males) ~50% by ~15 years, 75% by 25, 90% by 40; and (XLAS females) 10% by 40 and ~20% by 60. (kang2024acomprehensivereview pages 5-6)

Suggested HPO term: Sensorineural hearing impairment HP:0000407.

3.3 Ocular phenotypes

• Anterior lenticonus is described as pathognomonic; one review reports it in ~15% of males with XLAS. (kang2024acomprehensivereview pages 5-6)
• Other ocular findings include maculopathy with flecks; ocular abnormalities overall reported in ~30–40% of males and ~15% of females. (kang2024acomprehensivereview pages 3-5)

Suggested HPO terms (examples): - Anterior lenticonus HP:0001132 - Cataract HP:0000518 - Abnormal retinal pigmentation / dot-and-fleck retinopathy (phenotype-mapping required to exact HPO term)

3.4 Other features

Hypertension becomes more frequent with age, especially in males with XLAS. (kang2024acomprehensivereview pages 3-5)

Suggested HPO term: Hypertension HP:0000822.

3.5 Quality-of-life impact

Direct quantitative quality-of-life instrument results (e.g., SF-36, EQ-5D, PROMIS) were not available in the retrieved evidence.

4. Genetic / Molecular Information

4.1 Causal genes

• COL4A5 (X-linked), COL4A3 and COL4A4 (autosomal dominant/recessive), with digenic combinations reported. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 3-5)

4.2 Pathogenic variant classes and functional consequences

Across cohorts and variant interpretation guidance, pathogenic variants include missense (often glycine substitutions in Gly-X-Y collagen repeats), nonsense, frameshift, splice variants, and CNVs; splice variants may require functional confirmation (e.g., minigene assays). (chen2025novelcol4a3–col4a5variants pages 3-4, lee2024pathologicaldiagnosisof pages 2-5, savige2021consensusstatementon pages 1-2)

Example splice-variant mechanistic evidence (human): a COL4A5 intronic variant c.4298–20T>A was shown (minigene assay) to cause intron 46 retention and predicted impairment of α5(IV) structure, supporting classification as likely pathogenic with mild XLAS phenotype. (liang2023moleculardynamicsand pages 1-2)

4.3 Variant interpretation standards (ACMG/AMP refinement)

A consensus statement refined ACMG/AMP variant interpretation for COL4A3–COL4A5 and broadened recommended testing indications beyond the classic phenotype. Key challenges include hypomorphic variants, variable inheritance, and inability to define a universal benign MAF threshold. (savige2021consensusstatementon pages 1-2, savige2021consensusstatementon pages 2-3)

Direct abstract quote (Savige 2021): - “extended the indications for screening for pathogenic variants in the COL4A5, COL4A3 and COL4A4 genes beyond the classical Alport phenotype … to include persistent proteinuria, steroid-resistant nephrotic syndrome, focal and segmental glomerulosclerosis (FSGS), familial IgA glomerulonephritis and end-stage kidney failure without an obvious cause.” (savige2021consensusstatementon pages 1-2)

4.4 Modifier genes

Evidence from a small case series suggests co-occurring variants in podocyte/ECM genes (e.g., CRB2, PLCE1, MYO1E, NUP107, LAMA5, LAMB2) may modify severity (e.g., nephrotic syndrome, FSGS, ESKD), but authors emphasize uncertainty and need for validation. (lujinschi2025candidategeneticmodifiers pages 1-2, lujinschi2025candidategeneticmodifiers pages 2-4)

4.5 Epigenetics / chromosomal abnormalities

No disease-specific epigenetic or chromosomal-abnormality evidence was identified in the retrieved evidence set.

5. Environmental Information

No specific environmental toxin, pollution, occupational exposure, or infectious trigger evidence was identified in the retrieved evidence set as a causal contributor to Alport syndrome (a monogenic disorder). Lifestyle factors were also not described in a disease-specific manner in the retrieved evidence.

6. Mechanism / Pathophysiology

6.1 Core causal chain (current understanding)

1) Pathogenic COL4A3/4/5 variant → 2) defective assembly/stability of α3α4α5(IV) collagen network in GBM → 3) compromised filtration barrier integrity under physiologic pressure → 4) haematuria and progressive glomerular injury → 5) proteinuria and CKD progression to ESKD; with parallel basement-membrane pathology in cochlea/eye contributing to hearing/ocular phenotypes. (kang2024acomprehensivereview pages 1-3, torra2025diagnosismanagementand pages 1-2)

6.2 Fibrosis and inflammation (downstream mechanisms)

A mechanistic mouse study linked COL4A5 deficiency to renal fibrosis via HA/CD44/TGFβ signaling, proposing HAS2/CD44 as potential targets: “COL4A5 deficiency may lead to HAS2 overexpression and HA accumulation to activate CD44-TGFβ signaling, thereby promoting fibrosis”. ()

6.3 Suggested GO / CL terms (knowledge-base oriented; not evidence claims)

• GO biological process: extracellular matrix organization (GO:0030198); basement membrane organization (GO:0071711); collagen fibril organization (GO:0030199); renal fibrosis (commonly mapped to “extracellular matrix organization” + “response to TGF-beta”)
• Cell Ontology (CL): podocyte (CL:0000653); glomerular endothelial cell (CL:0002139); mesangial cell (CL:0000650)

7. Anatomical Structures Affected

7.1 Organ level

• Kidney (glomerulus/GBM) is primary. (torra2025diagnosismanagementand pages 1-2)
• Inner ear (cochlea) involvement manifests as sensorineural hearing loss. (kang2024acomprehensivereview pages 5-6)
• Eye involvement includes lens and retina findings (e.g., lenticonus, macular flecks). (kang2024acomprehensivereview pages 5-6)

7.2 Tissue/cell level and pathology localization

Renal biopsy pathology shows GBM ultrastructural abnormalities (thinning/thickening, irregularity, lamellation/basket-weaving) on electron microscopy; light microscopy changes are often nonspecific (including FSGS). (lee2024pathologicaldiagnosisof pages 2-5)

Visual evidence (electron microscopy + collagen IV staining patterns): representative EM and collagen IV staining patterns are shown in Lee 2024 Figures 2–3 (lee2024pathologicaldiagnosisof media 9c957d59, lee2024pathologicaldiagnosisof media 091648f1).

Suggested UBERON terms (examples): - Kidney UBERON:0002113 - Glomerular basement membrane UBERON:0005174 - Cochlea UBERON:0001684 - Lens capsule / retina (map to appropriate UBERON terms as needed)

8. Temporal Development

8.1 Onset

In a pediatric cohort, onset was often preschool-aged (1–6 years) in 65%. (chen2025novelcol4a3–col4a5variants pages 3-4)

8.2 Progression

A typical course described in reviews begins with microscopic haematuria, then proteinuria, then progressive CKD/ESKD. (kang2024acomprehensivereview pages 5-6)

9. Inheritance and Population

9.1 Inheritance patterns

• X-linked (COL4A5), autosomal recessive (biallelic COL4A3/COL4A4), autosomal dominant (heterozygous COL4A3/COL4A4), and digenic inheritance are all recognized. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 3-5)

9.2 Epidemiology

Multiple prevalence estimates appear across sources: - Guideline excerpt cites phenotype-based prevalence estimates ranging from 1:5,000 (Utah) to 1:17,000 (Sweden). (torra2025diagnosismanagementand pages 1-2) - Workshop-era population-genetic analysis cites X-linked prevalence ~1 in 2,000 (gnomAD-based) and reports rare heterozygous COL4 variants up to 0.94% in a UK population dataset, highlighting that genomic prevalence may exceed classic clinical estimates. (daga2022the2019and pages 2-3, daga2022the2019and pages 3-4)

9.3 Genotype–phenotype / prognosis statistics

From a 2024 review: - XLAS males: ~50% reach ESKD before age 20. (kang2024acomprehensivereview pages 5-6) - XLAS hearing loss: ~50% by ~15 years, 75% by 25, 90% by 40. (kang2024acomprehensivereview pages 5-6) - ARAS: ~62% progress to ESKD with mean ESKD age ~21 years; hearing loss ~64%; ocular manifestations ~17%. (kang2024acomprehensivereview pages 5-6) - ADAS: microhematuria ~92%; estimated kidney survival ~67 years. (kang2024acomprehensivereview pages 5-6)

10. Diagnostics

10.1 Clinical tests

• Urinalysis is emphasized as an effective screening test for persistent microhematuria and proteinuria. (kang2024acomprehensivereview pages 5-6)

10.2 Pathology (biopsy)

• Light microscopy is often nonspecific; EM provides key diagnostic ultrastructure: GBM thinning/thickening, irregularity, lamellation (“basket-weave”), intramembranous microspherules. (lee2024pathologicaldiagnosisof pages 2-5, lee2024pathologicaldiagnosisof media 9c957d59)
• Thin basement membrane disease thresholds cited: suspicion at GBM thickness ≤250 nm in adults (≤180 nm in children). (lee2024pathologicaldiagnosisof pages 2-5)
• Type IV collagen immunostaining patterns vary by inheritance; autosomal dominant cases may be missed by collagen staining alone. (lee2024pathologicaldiagnosisof pages 2-5, lee2024pathologicaldiagnosisof media 091648f1)

10.3 Genetic testing (recommended approach)

The ERKNet/ERA/ESPN guideline states: “Genetic diagnostics comprising joint analysis of COL4A3/4/5 genes is already the key diagnostic test during the initial evaluation” of individuals with persistent haematuria, proteinuria, unexplained kidney failure, FSGS of unknown cause, and possibly cystic kidney disease. (torra2025diagnosismanagementand pages 1-2)

Expanded testing indications: persistent proteinuria, steroid-resistant nephrotic syndrome, FSGS, familial IgA glomerulonephritis, and ESKD without an obvious cause. (savige2021consensusstatementon pages 1-2, savige2021consensusstatementon pages 2-3)

10.4 Differential diagnosis / phenocopies

The consensus statement notes phenocopies of Alport syndrome may include other predominantly haematuric disorders (examples are listed in the paper), supporting careful differential diagnosis when COL4 variants are not identified. (savige2021consensusstatementon pages 3-4)

11. Outcome / Prognosis

11.1 Major prognostic factors (evidence-based)

• Inheritance subtype and sex (e.g., males with XLAS have earlier and more severe progression; ARAS typically severe/early; ADAS generally later but variable). (kang2024acomprehensivereview pages 5-6)
• Proteinuria as a progression risk marker. (kang2024acomprehensivereview pages 3-5)

11.2 Kidney failure outcomes

Quantified outcomes by subtype are summarized in Sections 9.3 and artifact table; hard survival metrics (life expectancy) were not directly available in the retrieved evidence.

12. Treatment

12.1 Standard-of-care pharmacotherapy

RAS blockade (ACE inhibitor or ARB) is the main disease-modifying standard of care, started early to slow progression. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 8-10)

MAXO suggestions: ACE inhibitor therapy; Angiotensin receptor blocker therapy; Blood pressure control; Proteinuria management.

12.2 SGLT2 inhibitors (recent developments and trials)

The ERKNet/ERA/ESPN guideline notes SGLT2 inhibitors “may be added in adults with proteinuria and chronic kidney disease.” (torra2025diagnosismanagementand pages 1-2)

Clinical research is expanding into younger patients: - DOUBLE PRO-TECT Alport (NCT05944016) protocol: multicenter, randomized, double-blind, placebo-controlled; ages 10–39; randomized 2:1 to dapagliflozin 10 mg/day vs placebo for 48 weeks; primary endpoint change in UACR at week 48; key secondary eGFR change at week 52. () - Observational dapagliflozin effectiveness study (NCT06226896): prospective cohort comparing dapagliflozin+ACEi/ARB vs ACEi/ARB alone for 24 months; primary endpoint eGFR change at 24 months; secondary includes proteinuria change and composite progression outcomes. (NCT06226896 chunk 1)

MAXO suggestions: SGLT2 inhibitor therapy; Albuminuria reduction therapy.

12.3 microRNA-21 targeting (RG-012 / lademirsen)

• RG-012 (NCT03373786) phase 1 completed (n=4): primary outcomes adverse events and change in renal miR-21; involved renal biopsies pre/post dosing in Part A. (NCT03373786 chunk 1)
• Lademirsen/SAR339375 (NCT02855268) phase 2 terminated (n=43): annualized eGFR change at week 48 was a primary endpoint; terminated after futility analysis with “No unexpected safety findings”. (NCT02855268 chunk 1)

MAXO suggestions: Antisense oligonucleotide therapy; Clinical trial enrollment.

12.4 Bardoxolone methyl (CARDINAL) — efficacy signals vs outcome/safety concerns

A Bardoxolone methyl phase 2/3 program (CARDINAL) reported on-treatment eGFR differences versus placebo: - mean difference at 48 weeks +9.2 mL/min/1.73 m² (97.5% CI 5.1 to 13.4; p<0.001) - mean difference at 100 weeks +7.4 mL/min/1.73 m² (95% CI 3.1 to 11.7; p<0.001) - effect diminished after washout but persisted at week 52 (+5.4 mL/min/1.73 m²). (sarfraz2025systematicreviewof pages 3-5)

However, a detailed commentary emphasizes lack of demonstrated nephroprotection on hard outcomes and substantial safety signals: - “exactly the same number of patients (n = 3) in each group developed kidney failure” (ruggenenti2023thecardinaltrial pages 3-4) - liver enzyme elevations: “increase in liver enzymes in 70 of the 77 (90.9%) bardoxolone-treated patients” (ruggenenti2023thecardinaltrial pages 1-2) - FDA rejection and advisory committee unanimous vote against approval. (ruggenenti2023thecardinaltrial pages 4-5)

MAXO suggestions: NRF2 activator therapy (investigational; not recommended in practice based on safety/efficacy concerns); Drug safety monitoring.

12.5 Advanced therapeutics (gene/RNA/editing; recent research)

Recent preclinical and translational directions include exon-skipping, AAV-based gene therapy approaches, and iPSC-derived organoids for therapeutic testing. - Exon skipping (mouse model): podocyte-specific exon 21 skipping after disease onset “restored truncated collagen IV α5 expression, improved renal function, and ameliorated glomerular and tubular pathology,” including reversal of glomerular injury when initiated after proteinuria onset. () - Kidney organoid model (human iPSC): COL4A5 mutation-corrected iPSCs restored collagen α5(IV) expression in organoids; a chemical chaperone (4-phenyl butyric acid) showed potential to correct GBM abnormalities in mild phenotypes. ()

13. Prevention

Because Alport syndrome is genetic, prevention is primarily genetic and secondary prevention: - Cascade genetic testing to identify at-risk relatives was recommended in workshop-era guidance. (daga2022the2019and pages 2-3) - Early detection of haematuria/proteinuria and early initiation of kidney-protective therapy (RAS blockade) is emphasized as improving prognosis. (kang2024acomprehensivereview pages 8-10)

MAXO suggestions: Genetic counseling; Cascade genetic screening; Early ACE inhibitor therapy.

14. Other Species / Natural Disease

Naturally occurring Alport-like diseases in companion animals were not identified in the retrieved evidence.

15. Model Organisms and Experimental Models

15.1 Mouse models

• Col4a3−/− mice are widely used and show ocular anomalies similar to human AS; studies describe altered collagen IV expression and retinal/corneal/lens abnormalities. ()
• A novel Col4a5 splicing-mutation mouse (CRISPR/Cas9) showed progressive kidney deterioration, fibrosis, and immune cell infiltration, serving as an XLAS model. ()

15.2 Human in vitro models

• iPSC-derived collagen α5(IV)-expressing kidney organoids model mild vs severe AS and can be used for drug discovery and testing restoration strategies. ()

Recent developments (2023–2024 emphasis) and real-world implementation highlights

• Genotype-first diagnosis: guideline-level recommendation for joint COL4A3/4/5 analysis as key initial test (implementation: broader NGS adoption, reduced need for biopsy in many cases). (torra2025diagnosismanagementand pages 1-2, lee2024pathologicaldiagnosisof pages 2-5)
• Expanded testing indications beyond classical triad to include FSGS and unexplained ESKD—reflecting genomic medicine’s reclassification of glomerular diseases. (savige2021consensusstatementon pages 1-2, savige2021consensusstatementon pages 2-3)
• SGLT2 inhibitor movement into AS: guideline “may be added” for proteinuric adults plus multiple ongoing/proposed studies including pediatric RCT design. (torra2025diagnosismanagementand pages 1-2)
• miR-21 targeting and other molecular therapies: early-phase RG-012 completed with biomarker endpoints; lademirsen terminated for futility (showing the field’s iterative learning). (NCT03373786 chunk 1, NCT02855268 chunk 1)

Source URLs and publication dates (where available in evidence)

• ERKNet/ERA/ESPN guideline (published Dec 2025; labeled “2024 guideline”): https://doi.org/10.1093/ndt/gfae265 (torra2025diagnosismanagementand pages 1-2)
• Kang et al., comprehensive review (Sep 2024): https://doi.org/10.23876/j.krcp.24.065 (kang2024acomprehensivereview pages 1-3)
• Lee et al., pathological diagnosis (Aug 2024): https://doi.org/10.23876/j.krcp.24.063 (lee2024pathologicaldiagnosisof pages 2-5)
• Savige et al., molecular diagnostics consensus (Apr 2021): https://doi.org/10.1038/s41431-021-00858-1 (savige2021consensusstatementon pages 1-2)
• Daga et al., international workshops report (Mar 2022): https://doi.org/10.1038/s41431-022-01075-0 (daga2022the2019and pages 2-3)
• Ruggenenti commentary on CARDINAL (Feb 2023): https://doi.org/10.1159/000529471 (ruggenenti2023thecardinaltrial pages 1-2)
• ClinicalTrials.gov: NCT02855268; NCT03373786; NCT06226896 (NCT06226896 chunk 1, NCT03373786 chunk 1, NCT02855268 chunk 1)

Limitations of this report (evidence access)

• PMID-specific citations were requested; however, PMIDs were not available in the retrieved evidence snippets for most sources, and this report therefore cites using the provided context IDs plus DOI/URL where available.
• Orphanet, ICD, and MeSH identifiers could not be extracted from the available tool-retrieved documents.
• Several therapeutic and mechanistic claims in the field (e.g., additional 2023–2024 RCTs or specific registry outcomes) may exist but were not accessible in the retrieved evidence set and are not stated here.

References

1. (torra2025diagnosismanagementand pages 1-2): Roser Torra, Beata Lipska-Zietkiewicz, Frederic Acke, Corinne Antignac, Jan Ulrich Becker, Emilie Cornec-Le Gall, Albertien M van Eerde, Nicolas Feltgen, Rossella Ferrari, Daniel P Gale, Susie Gear, Oliver Gross, Stefanie Haeberle, Laurence Heidet, Rachel Lennon, Laura Massella, Kristina Pfau, Maria del Prado Venegas Pizarro, Rezan Topaloglu, Tanja Wlodkowski, Heidi Zealey, Oana Ailioaie, Marina Aksenova, Peter Barany, Moumita Barua, Elisa Benetti, Lisa Bonebrake, Olivier Bonny, Antonia Bouts, Olivia Boyer, Gianluca Caridi, Cristina Castro-Alonso, Kathleen Claes, Peter Conlon, George Claudiu Costea, Stéphane Decramer, Constantinos Deltas, Erol Demir, Nathalie Demoulin, Mark Eijgelsheim, Francesco Emma, Frances Flinter, Monica Furlano, Danica Galešić Ljubanović, Valentine Gillion, Ana Marta Gomes, Dieter Haffner, Julia Hoefele, Svetlana Jovicic Pavlovic, Clifford Kashtan, Stefan Kohl, Martin Konrad, Matjaž Kopač, Sandrine Lemoine, Max Christoph Liebau, Francesca Lugani, Alvaro Madrid, Andrew Mallett, Antonio Mastrangelo, Anamarija Meglič, Esther Meijer, Jeffrey Miner, Sevgı Mır, Kar Hui Ng, João Paulo Oliveira, Maria Vanessa Perez Gomez, Anna Maria Pinto, Ann Raes, Michelle Rheault, Judy Savige, Christoph Schwarz, Angel Manuel Sevillano Prieto, Ekamol Tantisattamo, Velibor Tasic, Kálmán Tory, Neil Turner, Andre Weinstock, and Izabela Zakrocka. Diagnosis, management and treatment of the alport syndrome – 2024 guideline on behalf of erknet, era and espn. Nephrology Dialysis Transplantation, 40:1091-1106, Dec 2025. URL: https://doi.org/10.1093/ndt/gfae265, doi:10.1093/ndt/gfae265. This article has 43 citations and is from a domain leading peer-reviewed journal.

2. (kang2024acomprehensivereview pages 5-6): Eunjeong Kang, Byung Hwa Park, Hajeong Lee, Hee Gyung Kang, Ji Hyun Kim, Ye Na Kim, Yeonsoon Jung, Hark Rim, and Ho Sik Shin. A comprehensive review of alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations. Kidney Research and Clinical Practice, 44:566-575, Sep 2024. URL: https://doi.org/10.23876/j.krcp.24.065, doi:10.23876/j.krcp.24.065. This article has 6 citations.

3. (liang2023moleculardynamicsand pages 1-2): Lei Liang, Haotian Wu, Zeyu Cai, and Jianrong Zhao. Molecular dynamics and minigene assay of new splicing variant c.4298-20t>a of col4a5 gene that cause alport syndrome. Frontiers in Genetics, Feb 2023. URL: https://doi.org/10.3389/fgene.2023.1059322, doi:10.3389/fgene.2023.1059322. This article has 9 citations and is from a peer-reviewed journal.

4. (kang2024acomprehensivereview pages 1-3): Eunjeong Kang, Byung Hwa Park, Hajeong Lee, Hee Gyung Kang, Ji Hyun Kim, Ye Na Kim, Yeonsoon Jung, Hark Rim, and Ho Sik Shin. A comprehensive review of alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations. Kidney Research and Clinical Practice, 44:566-575, Sep 2024. URL: https://doi.org/10.23876/j.krcp.24.065, doi:10.23876/j.krcp.24.065. This article has 6 citations.

5. (kang2024acomprehensivereview pages 3-5): Eunjeong Kang, Byung Hwa Park, Hajeong Lee, Hee Gyung Kang, Ji Hyun Kim, Ye Na Kim, Yeonsoon Jung, Hark Rim, and Ho Sik Shin. A comprehensive review of alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations. Kidney Research and Clinical Practice, 44:566-575, Sep 2024. URL: https://doi.org/10.23876/j.krcp.24.065, doi:10.23876/j.krcp.24.065. This article has 6 citations.

6. (daga2022the2019and pages 2-3): Sergio Daga, Jie Ding, Constantinos Deltas, Judy Savige, Beata S. Lipska-Ziętkiewicz, Julia Hoefele, Frances Flinter, Daniel P. Gale, Marina Aksenova, Hirofumi Kai, Laura Perin, Moumita Barua, Roser Torra, Jeff H. Miner, Laura Massella, Danica Galešić Ljubanović, Rachel Lennon, Andrè B. Weinstock, Bertrand Knebelmann, Agne Cerkauskaite, Susie Gear, Oliver Gross, A. Neil Turner, Margherita Baldassarri, Anna Maria Pinto, and Alessandra Renieri. The 2019 and 2021 international workshops on alport syndrome. European Journal of Human Genetics, 30:507-516, Mar 2022. URL: https://doi.org/10.1038/s41431-022-01075-0, doi:10.1038/s41431-022-01075-0. This article has 41 citations and is from a domain leading peer-reviewed journal.

7. (savige2021consensusstatementon pages 1-2): Judy Savige, Helen Storey, Elizabeth Watson, Jens Michael Hertz, Constantinos Deltas, Alessandra Renieri, Francesca Mari, Pascale Hilbert, Pavlina Plevova, Peter Byers, Agne Cerkauskaite, Martin Gregory, Rimante Cerkauskiene, Danica Galesic Ljubanovic, Francesca Becherucci, Carmela Errichiello, Laura Massella, Valeria Aiello, Rachel Lennon, Louise Hopkinson, Ania Koziell, Adrian Lungu, Hansjorg Martin Rothe, Julia Hoefele, Miriam Zacchia, Tamara Nikuseva Martic, Asheeta Gupta, Albertien van Eerde, Susie Gear, Samuela Landini, Viviana Palazzo, Laith al-Rabadi, Kathleen Claes, Anniek Corveleyn, Evelien Van Hoof, Micheel van Geel, Maggie Williams, Emma Ashton, Hendica Belge, Elisabeth Ars, Agnieszka Bierzynska, Concetta Gangemi, and Beata S. Lipska-Ziętkiewicz. Consensus statement on standards and guidelines for the molecular diagnostics of alport syndrome: refining the acmg criteria. European Journal of Human Genetics, 29:1186-1197, Apr 2021. URL: https://doi.org/10.1038/s41431-021-00858-1, doi:10.1038/s41431-021-00858-1. This article has 137 citations and is from a domain leading peer-reviewed journal.

8. (daga2022the2019and pages 1-2): Sergio Daga, Jie Ding, Constantinos Deltas, Judy Savige, Beata S. Lipska-Ziętkiewicz, Julia Hoefele, Frances Flinter, Daniel P. Gale, Marina Aksenova, Hirofumi Kai, Laura Perin, Moumita Barua, Roser Torra, Jeff H. Miner, Laura Massella, Danica Galešić Ljubanović, Rachel Lennon, Andrè B. Weinstock, Bertrand Knebelmann, Agne Cerkauskaite, Susie Gear, Oliver Gross, A. Neil Turner, Margherita Baldassarri, Anna Maria Pinto, and Alessandra Renieri. The 2019 and 2021 international workshops on alport syndrome. European Journal of Human Genetics, 30:507-516, Mar 2022. URL: https://doi.org/10.1038/s41431-022-01075-0, doi:10.1038/s41431-022-01075-0. This article has 41 citations and is from a domain leading peer-reviewed journal.

9. (daga2022the2019and pages 3-4): Sergio Daga, Jie Ding, Constantinos Deltas, Judy Savige, Beata S. Lipska-Ziętkiewicz, Julia Hoefele, Frances Flinter, Daniel P. Gale, Marina Aksenova, Hirofumi Kai, Laura Perin, Moumita Barua, Roser Torra, Jeff H. Miner, Laura Massella, Danica Galešić Ljubanović, Rachel Lennon, Andrè B. Weinstock, Bertrand Knebelmann, Agne Cerkauskaite, Susie Gear, Oliver Gross, A. Neil Turner, Margherita Baldassarri, Anna Maria Pinto, and Alessandra Renieri. The 2019 and 2021 international workshops on alport syndrome. European Journal of Human Genetics, 30:507-516, Mar 2022. URL: https://doi.org/10.1038/s41431-022-01075-0, doi:10.1038/s41431-022-01075-0. This article has 41 citations and is from a domain leading peer-reviewed journal.

10. (adone2023alportsyndromea pages 3-4): Avanti Adone and Ashish P Anjankar. Alport syndrome: a comprehensive review. Cureus, Oct 2023. URL: https://doi.org/10.7759/cureus.47129, doi:10.7759/cureus.47129. This article has 24 citations.

11. (lee2024pathologicaldiagnosisof pages 2-5): Kyoung Bun Lee, Minsun Jung, and Beom Jin Lim. Pathological diagnosis of alport syndrome. Kidney Research and Clinical Practice, 44:406-410, Aug 2024. URL: https://doi.org/10.23876/j.krcp.24.063, doi:10.23876/j.krcp.24.063. This article has 3 citations.

12. (lee2024pathologicaldiagnosisof media 9c957d59): Kyoung Bun Lee, Minsun Jung, and Beom Jin Lim. Pathological diagnosis of alport syndrome. Kidney Research and Clinical Practice, 44:406-410, Aug 2024. URL: https://doi.org/10.23876/j.krcp.24.063, doi:10.23876/j.krcp.24.063. This article has 3 citations.

13. (lee2024pathologicaldiagnosisof media 091648f1): Kyoung Bun Lee, Minsun Jung, and Beom Jin Lim. Pathological diagnosis of alport syndrome. Kidney Research and Clinical Practice, 44:406-410, Aug 2024. URL: https://doi.org/10.23876/j.krcp.24.063, doi:10.23876/j.krcp.24.063. This article has 3 citations.

14. (savige2021consensusstatementon pages 2-3): Judy Savige, Helen Storey, Elizabeth Watson, Jens Michael Hertz, Constantinos Deltas, Alessandra Renieri, Francesca Mari, Pascale Hilbert, Pavlina Plevova, Peter Byers, Agne Cerkauskaite, Martin Gregory, Rimante Cerkauskiene, Danica Galesic Ljubanovic, Francesca Becherucci, Carmela Errichiello, Laura Massella, Valeria Aiello, Rachel Lennon, Louise Hopkinson, Ania Koziell, Adrian Lungu, Hansjorg Martin Rothe, Julia Hoefele, Miriam Zacchia, Tamara Nikuseva Martic, Asheeta Gupta, Albertien van Eerde, Susie Gear, Samuela Landini, Viviana Palazzo, Laith al-Rabadi, Kathleen Claes, Anniek Corveleyn, Evelien Van Hoof, Micheel van Geel, Maggie Williams, Emma Ashton, Hendica Belge, Elisabeth Ars, Agnieszka Bierzynska, Concetta Gangemi, and Beata S. Lipska-Ziętkiewicz. Consensus statement on standards and guidelines for the molecular diagnostics of alport syndrome: refining the acmg criteria. European Journal of Human Genetics, 29:1186-1197, Apr 2021. URL: https://doi.org/10.1038/s41431-021-00858-1, doi:10.1038/s41431-021-00858-1. This article has 137 citations and is from a domain leading peer-reviewed journal.

15. (chen2025novelcol4a3–col4a5variants pages 3-4): Ji-Yu Chen, Xue-Mei Jiang, Ya-Bin Liao, Yan-Hua Zhang, Mi-feng Yang, Jing-Jing Cui, Jing Wang, Jia Zhang, Hong-Ye Wang, and Bo Zhao. Novel col4a3–col4a5 variants and digenic inheritance in pediatric alport syndrome from southwestern china. Scientific Reports, Aug 2025. URL: https://doi.org/10.1038/s41598-025-17027-9, doi:10.1038/s41598-025-17027-9. This article has 0 citations and is from a peer-reviewed journal.

16. (kang2024acomprehensivereview pages 8-10): Eunjeong Kang, Byung Hwa Park, Hajeong Lee, Hee Gyung Kang, Ji Hyun Kim, Ye Na Kim, Yeonsoon Jung, Hark Rim, and Ho Sik Shin. A comprehensive review of alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations. Kidney Research and Clinical Practice, 44:566-575, Sep 2024. URL: https://doi.org/10.23876/j.krcp.24.065, doi:10.23876/j.krcp.24.065. This article has 6 citations.

17. (ruggenenti2023thecardinaltrial pages 1-2): Piero Ruggenenti. The cardinal trial of bardoxolone methyl in alport syndrome: when marketing interests prevail over patients clinical needs. Nephron, 147:465-469, Feb 2023. URL: https://doi.org/10.1159/000529471, doi:10.1159/000529471. This article has 16 citations.

18. (ruggenenti2023thecardinaltrial pages 3-4): Piero Ruggenenti. The cardinal trial of bardoxolone methyl in alport syndrome: when marketing interests prevail over patients clinical needs. Nephron, 147:465-469, Feb 2023. URL: https://doi.org/10.1159/000529471, doi:10.1159/000529471. This article has 16 citations.

19. (sarfraz2025systematicreviewof pages 3-5): Zouina Sarfraz, Ayesha Khan, Maryyam Liaqat, Aden Khan, Faheem Javad, Meher Saleem, Azza Sarfraz, Musfira Khalid, Muzna Sarfraz, Manish Kc, and Omar Irfan. Systematic review of management strategies for alport syndrome: implications for male patients. Health Science Reports, Mar 2025. URL: https://doi.org/10.1002/hsr2.70595, doi:10.1002/hsr2.70595. This article has 2 citations and is from a peer-reviewed journal.

20. (ruggenenti2023thecardinaltrial pages 4-5): Piero Ruggenenti. The cardinal trial of bardoxolone methyl in alport syndrome: when marketing interests prevail over patients clinical needs. Nephron, 147:465-469, Feb 2023. URL: https://doi.org/10.1159/000529471, doi:10.1159/000529471. This article has 16 citations.

21. (NCT03373786 chunk 1): A Study of RG-012 in Subjects With Alport Syndrome. Genzyme, a Sanofi Company. 2017. ClinicalTrials.gov Identifier: NCT03373786

22. (NCT02855268 chunk 1): Study of Lademirsen (SAR339375) in Patients With Alport Syndrome. Genzyme, a Sanofi Company. 2019. ClinicalTrials.gov Identifier: NCT02855268

23. (NCT06226896 chunk 1): Zhi-Hong Liu, MD. Effects of Dapagliflozin on Progression of Alport Syndrome. Nanjing University School of Medicine. 2023. ClinicalTrials.gov Identifier: NCT06226896

24. (NCT02378805 chunk 2): Prof. Dr. O. Gross. Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome. University Hospital Goettingen. 1995. ClinicalTrials.gov Identifier: NCT02378805

25. (lujinschi2025candidategeneticmodifiers pages 1-2): Ștefan Nicolaie Lujinschi, Bogdan Marian Sorohan, Bogdan Obrișcă, Alexandra Vrabie, Elena Rusu, Diana Zilișteanu, Camelia Achim, Andreea Gabriella Andronesi, and Gener Ismail. Candidate genetic modifiers in alport syndrome: a case series. Life, 15:298, Feb 2025. URL: https://doi.org/10.3390/life15020298, doi:10.3390/life15020298. This article has 2 citations.

26. (lujinschi2025candidategeneticmodifiers pages 2-4): Ștefan Nicolaie Lujinschi, Bogdan Marian Sorohan, Bogdan Obrișcă, Alexandra Vrabie, Elena Rusu, Diana Zilișteanu, Camelia Achim, Andreea Gabriella Andronesi, and Gener Ismail. Candidate genetic modifiers in alport syndrome: a case series. Life, 15:298, Feb 2025. URL: https://doi.org/10.3390/life15020298, doi:10.3390/life15020298. This article has 2 citations.

27. (savige2021consensusstatementon pages 3-4): Judy Savige, Helen Storey, Elizabeth Watson, Jens Michael Hertz, Constantinos Deltas, Alessandra Renieri, Francesca Mari, Pascale Hilbert, Pavlina Plevova, Peter Byers, Agne Cerkauskaite, Martin Gregory, Rimante Cerkauskiene, Danica Galesic Ljubanovic, Francesca Becherucci, Carmela Errichiello, Laura Massella, Valeria Aiello, Rachel Lennon, Louise Hopkinson, Ania Koziell, Adrian Lungu, Hansjorg Martin Rothe, Julia Hoefele, Miriam Zacchia, Tamara Nikuseva Martic, Asheeta Gupta, Albertien van Eerde, Susie Gear, Samuela Landini, Viviana Palazzo, Laith al-Rabadi, Kathleen Claes, Anniek Corveleyn, Evelien Van Hoof, Micheel van Geel, Maggie Williams, Emma Ashton, Hendica Belge, Elisabeth Ars, Agnieszka Bierzynska, Concetta Gangemi, and Beata S. Lipska-Ziętkiewicz. Consensus statement on standards and guidelines for the molecular diagnostics of alport syndrome: refining the acmg criteria. European Journal of Human Genetics, 29:1186-1197, Apr 2021. URL: https://doi.org/10.1038/s41431-021-00858-1, doi:10.1038/s41431-021-00858-1. This article has 137 citations and is from a domain leading peer-reviewed journal.